Burris HA, Beck JT, Rugo HS, Baselga J, Lebrun F, Taran T, Bennett L. Health-related quality of life in advanced breast cancer patients treated with everolimus and exemestane versus exemestane monotherapy. Poster presented at the ESMO 37th Congress; September 28, 2012. Vienna, Austria.
Zhou X, Sherrill B, Wu Y, Bennett L, Wang J. Evaluating effects of changing treatments in longitudinal studies. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 5, 2012. Barcelona.
Zafar SY, Grothey A, Bekaii-Saab T, Bendell J, Sherrill B, Bennett L, Mun Y, Sersch M, Dalal D, Hurwitz HI. Survival among metastatic colorectal cancer (MCRC) patients treated in a randomized controlled trial (RCT) vs an observational cohort study (OCS). Poster presented at the 37th Annual Congress of the European Society for Medical Oncology; September 1, 2012. [abstract] Ann Oncol. 2012 Sep 1; 23(Suppl. 9):191.
Burris H, Beck JT, Rugo H, Baselga J, Lebrun F, Taran T, Bennett L, Ricci J, Sahmoud T, Hortobagyi GN. Health-related quality of life (QoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane monotherapy. Poster presented at the ESMO 2012 Conference; September 2012. [abstract] Ann Oncol. 2012 Sep; 23(Suppl. 9):121-2.
Zafar Y, Grothey A, Bekaii-Saab TS, Bendell J, Sherrill EH, Bennett L. Survival among metastatic colorectal cancer patients treated in a randomized controlled trial versus an observational cohort study. Poster presented at the ESMO 37th Congress; September 2012. Vienna, Austria.
Beck JT, Rugo HS, Burris HA, Baselga J, Noguchi S, Gnant M, Pritchard KI, Bennett L. BOLERO-2: health-related quality of life in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane. Poster presented at the 2012 Annual Meeting of the American Society of Clinical Oncology; June 2012. Chicago, IL.